MAIA · MAIA Biotechnology, Inc.
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MAIA
this stock
MAIA Biotechnology, Inc.
|
$76.00M | -18.3% | — | — | 4.8% |
|
ONC
BeOne Medicines Ltd.
|
$465.49B | +6.0% | +22179.2% | 947.3 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.26B | +6.3% | +46.2% | 28.6 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.02B | -4.2% | +20.8% | 18.3 | 3.4% |
|
ARGX
Argenx SE
|
$54.59B | +3.8% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MAIA | -2.3% | -12.6% | -34.6% | -13.2% | -18.3% |
| SPY | +0.5% | -0.6% | +9.5% | -0.7% | +8.8% |
| vs SPY | -2.8% | -12.0% | -44.0% | -12.5% | -27.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.